214 related articles for article (PubMed ID: 12140036)
1. Corneal opacities associated with NTBC treatment.
Ahmad S; Teckman JH; Lueder GT
Am J Ophthalmol; 2002 Aug; 134(2):266-8. PubMed ID: 12140036
[TBL] [Abstract][Full Text] [Related]
2. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
Gissen P; Preece MA; Willshaw HA; McKiernan PJ
J Inherit Metab Dis; 2003; 26(1):13-6. PubMed ID: 12872835
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.
Kassel R; Sprietsma L; Rudnick DA
J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):e5-7. PubMed ID: 23838819
[No Abstract] [Full Text] [Related]
4. Confocal microscopy of corneal crystals in a patient with hereditary tyrosinemia type I, treated with NTBC.
Schauwvlieghe PP; Jaeken J; Kestelyn P; Claerhout I
Cornea; 2013 Jan; 32(1):91-4. PubMed ID: 22495034
[TBL] [Abstract][Full Text] [Related]
5. Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury.
Lock EA; Gaskin P; Ellis M; Provan WM; Smith LL
Toxicol Appl Pharmacol; 2006 Aug; 215(1):9-16. PubMed ID: 16580702
[TBL] [Abstract][Full Text] [Related]
6. The effect of a low-protein diet and dietary supplementation of threonine on tyrosine and 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinemia, and the activity of enzymes involved in tyrosine catabolism in the rat.
Lock EA; Gaskin P; Ellis MK; Robinson M; Provan WM; Smith LL
Toxicol Appl Pharmacol; 1998 May; 150(1):125-32. PubMed ID: 9630461
[TBL] [Abstract][Full Text] [Related]
7. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
Holme E; Lindstedt S
J Inherit Metab Dis; 1998 Aug; 21(5):507-17. PubMed ID: 9728331
[TBL] [Abstract][Full Text] [Related]
8. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
Med Lett Drugs Ther; 2016 Oct; 58(1505):e132. PubMed ID: 27701365
[No Abstract] [Full Text] [Related]
9. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.
van Ginkel WG; Rodenburg IL; Harding CO; Hollak CEM; Heiner-Fokkema MR; van Spronsen FJ
Paediatr Drugs; 2019 Dec; 21(6):413-426. PubMed ID: 31667718
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers.
Hall MG; Wilks MF; Provan WM; Eksborg S; Lumholtz B
Br J Clin Pharmacol; 2001 Aug; 52(2):169-77. PubMed ID: 11488774
[TBL] [Abstract][Full Text] [Related]
11. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
[TBL] [Abstract][Full Text] [Related]
12. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1-3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat.
Lock EA; Gaskin P; Ellis MK; Provan WM; Robinson M; Smith LL; Prisbylla MP; Mutter LC
Toxicol Appl Pharmacol; 1996 Dec; 141(2):439-47. PubMed ID: 8975769
[TBL] [Abstract][Full Text] [Related]
13. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.
Al-Dhalimy M; Overturf K; Finegold M; Grompe M
Mol Genet Metab; 2002 Jan; 75(1):38-45. PubMed ID: 11825062
[TBL] [Abstract][Full Text] [Related]
14. [Evolution of a case of tyrosinemia type I treated with NTBC].
Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E
An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
[TBL] [Abstract][Full Text] [Related]
15. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.
Lock EA; Ellis MK; Gaskin P; Robinson M; Auton TR; Provan WM; Smith LL; Prisbylla MP; Mutter LC; Lee DL
J Inherit Metab Dis; 1998 Aug; 21(5):498-506. PubMed ID: 9728330
[TBL] [Abstract][Full Text] [Related]
16. NTBC and alkaptonuria.
Anikster Y; Nyhan WL; Gahl WA
Am J Hum Genet; 1998 Sep; 63(3):920-1. PubMed ID: 9718357
[No Abstract] [Full Text] [Related]
17. Predicting tyrosinaemia: a mathematical model of 4-hydroxyphenylpyruvate dioxygenase inhibition by nitisinone in rats.
Ward JP; Dunster JL; Derks G; Mistry P; Salazar JD
Math Med Biol; 2017 Sep; 34(3):335-390. PubMed ID: 27305933
[TBL] [Abstract][Full Text] [Related]
18. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC.
Thimm E; Richter-Werkle R; Kamp G; Molke B; Herebian D; Klee D; Mayatepek E; Spiekerkoetter U
J Inherit Metab Dis; 2012 Mar; 35(2):263-8. PubMed ID: 22069142
[TBL] [Abstract][Full Text] [Related]
19. Corneal depositions in tyrosinaemia type I during treatment with Nitisinone.
Wisse RP; Wittebol-Post D; Visser G; van der Lelij A
BMJ Case Rep; 2012 Nov; 2012():. PubMed ID: 23203167
[TBL] [Abstract][Full Text] [Related]
20. Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism.
Hanauske-Abel HM; Popowicz A; Remotti H; Newfield RS; Levy J
J Pediatr Gastroenterol Nutr; 2002 Jul; 35(1):73-8. PubMed ID: 12142814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
